ClinicalTrials.gg
CompletedNCT03295097Updated Feb 17, 2021

Characteristics and Clinical Implications of a Clinical Decision Support System

An interventional study of Clinical Decision Support System in Chronic Illness, Opioid Use and Palliative Care, sponsored by Hospice of Henderson County, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-17.

Sponsored by Hospice of Henderson County, Inc. · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The investigators propose to study the feasibility, acceptability, usability and outcomes of a new clinical decision support system for clinicians of opioid therapy in the context of specialist palliative care for serious chronic illness. The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment. Investigators will conduct clinician survey's to collection information about the clinical decision support system. Investigators will also conduct patient related questionnaires to determine any benefits or improvements in quality of life and symptom management from the clinical decision support system.

02

Conditions studied

  • Chronic Illness
  • Opioid Use
  • Palliative Care

Browse trials for

Keywords

  • pharmacogenomics
03

In context

Chronic Disease

781 studies on the registry are indexed under Chronic Disease; 144 are open to participants now.

This study's enrollment of 100 is below the median of 140 across 582 interventional studies indexed under Chronic Disease.

Browse Chronic Disease studies →

Lead sponsor

Hospice of Henderson County, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinicians will be eligible if:

  1. Physicians or nurse practitioners who are practicing hospice and palliative care
  2. Responsible for making and implementing decisions about opioid therapy for pain

Patients will be identified by their treating clinicians. Patients will be eligible if:

  1. > 18 years of age
  2. Palliative Performance Score ≥ 30%
  3. Reside in the community or at a nursing home
  4. Have >1 serious chronic illness
  5. Have an assessed life-expectancy of at least 4 weeks
  6. Have a history of pain and have been taking prescribed opioid medication with a regimen that provides a minimum dose of 20 mg morphine or equivalent per day in scheduled doses for at least one week prior to recruitment
  7. Is expected to continue opioid therapy for the duration of study participation
  8. Is taking > 4 non-opioid medications, each in a regimen providing continuous treatment of pain or another disorder
  9. Is expected to continue drug therapy for the duration of study participation
  10. Able to read, understand, and provide to participate

Exclusion criteria

Exclusion Criteria:

There are no exclusion criteria for clinicians.

Patients will be excluded if:

  1. Pregnant women or women trying to become pregnant or nursing. Women of must use an acceptable method of for the duration of the study. (acceptable forms are oral birth control pills, condoms in combination with spermicide foam, IUD, transdermal patches, birth control implants, vaginal ring)
  2. Palliative Performance Score \<30%
  3. Have taken an product in the last 30 days
  4. Current use of illicit substances
  5. Immediate family members of site staff, or site staff may not be enrolled in the study without first obtaining IRB authorization
  6. Any other medical or physical abnormality, disease, or disorder that would prohibit the patient from completing study procedures in the judgement of the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Other
    Clinical Decision Support System

    The Clinical Decision Support System is composed of pharmacogenomic results and a pharmacist evaluated drug to drug interaction review. This system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions.

    Other: Clinical Decision Support System

Interventions

  • OtherClinical Decision Support System

    The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.

06

What researchers measure

Primary outcomes

  1. Clinician Feasibility

    Clinical questionnaire to determine feasibility of the system

    Time frame: through study completion, an average of 24 months

  2. Clinician Usability

    Clinical questionnaire to determine usability of the system

    Time frame: through study completion, an average of 24 months

Secondary outcomes

  1. Patient Quality of Life

    Functional Assessment of Chronic Illness - Palliative (FACIT-PAL)

    Time frame: through study completion,an average of 24 months

  2. Patient Pain

    Numerical Rating Scale to assess pain

    Time frame: through study completion, an average of 24 months

07

Study locations

2 sites
  • MJHS Hospice and Palliative Care
    New York, New York 10006, United States
  • Hospice of Henderson County, Inc. d/b/a Four Seasons Compassion for Life
    Flat Rock, North Carolina 28731, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jan 2020, 22 months.

Of 318 non-industry interventional studies with no phase under Chronic Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's 22 months is close to that.

Counting every sponsor, half of 328 studies reached it within 21 months; a quarter within 11 and three quarters within 33.

Chronic Disease covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2017
First posted
Sep 27, 2017
StartActual
Mar 8, 2018
Primary completionActual
Jan 21, 2020
CompletionActual
Jan 21, 2020
Last update
Feb 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03295097
Lead sponsor
Hospice of Henderson County, Inc.
Collaborators
Tabula Rasa HealthCare
Responsible party
Sponsor
First posted
Sep 27, 2017
Start date
Mar 8, 2018
Primary completion
Jan 21, 2020
Completion
Jan 21, 2020
Last update
Feb 17, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion